Neladalkib is a precision-engineered, brain-penetrant small-molecule inhibitor designed specifically to target ALK-positive non-small cell lung cancer and other resistant solid tumors. Developed to overcome common resistance mutations and neurological side effects associated with earlier generation tyrosine kinase inhibitors, it represents a potential best-in-class targeted oncology therapeutic option.